There is general agreement in the scientific community on the need to improve carcinogenicity testing and the assessment of human carcinogenic risk and to incorporate more information on mechanisms and modes of action into the risk assessment process. Advances in molecular biology have identified a growing number of genes such as protooncogenes and tumorsuppressor genes that are highly conserved across species and are assocjated with a wide variety of human and animal cancers. In vivo transgenic rodent models incorporating such mechanisms are used to identify mechanisms involved in tumor formation and as selective tests for carcinogens. Transgenic methods can be considered an extension of genetic manipulation by selective breeding, which long has been employed in science and agriculture. The use of two rodent species in carcinogenicity testing is especially important for identifying transspecies carcinogens. The capacity of a substance to induce neoplasia across species suggests that the mechanism(s) involved in the induction of the neoplasia are conserved and therefore may have significance for humans. Based on available information there is sufficient experience with some in vivo transgenic rodent carcinogenicity models to support their application as complementary second species studies in conjunction with a single 2-year rodent carcinogenicity study. The optional substitution of a second 2-year rodent carcinogenicity study with an alternative study such as an in vivo transgenic carcinogenicity study is part of the International Conference on Harmonization guidance Si B: Testing for Carcinogenicity of Pharmaceuticals. This guidance is intended to be flexible enough to accommodate a wide range of possible carcinogenicity assessment models currently under consideration or models that may be developed in the future. The use of an in vivo transgenic mouse model in place of a second 2-year mouse study will improve the assessment of carcinogenic risk by contributing insights into the mechanisms of tumorigenesis and potential human relevance not available from a standard 2-year bioassay. It is envisioned that this will stimulate the further development of more efficient and relevant methods for identifying and assessing potential human carcinogenic risk, which will benefit public health.
Introduction
Application of new approaches for regulatory agencies in part because of the assessment of the carcinogenic potential of complexity of the carcinogenic process. pharmaceuticals such as in vivo transgenic Cancer is a multistage process associated rodent models is a major challenge for with changes in the integrity or expression the scientific community, industry, and of genomic DNA (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) .
Transgenic rodents have yielded important new insights into carcinogenic mechanisms and some transgenic models also have potential application for identifying carcinogens (14, 15) . Transgenic methods can be considered an extension of genetic manipulation by selective breeding that long has been employed in science and agriculture to produce animals with desired phenotypic characteristics and relatively uniform genotype. Transgenic animals useful as cancer models have been developed that contain regulated transgenes, unexpressed reporter genes, or knocked-out alleles of tumor-suppressor genes. Information derived from in vivo transgenic carcinogenicity models can contribute additional insights (16, 17) into the mechanism of carcinogenesis and possible human risk that may be of greater value and potential relevance to humans than information from a second conventional 2-year rodent study. Transgenic (27) .
Site concordance is not as important as might be anticipated for pharmaceuticals except, for example, when specific receptormediated mechanisms of carcinogenesis are implicated. The tumor site concordance of rats and mice is relatively poor. In the U.S. FDA, U.S. NTP, and CPD databases only 22, 26, and 33%, respectively, of all compounds with positive findings produced tumor findings in at least one common site in the rat and mouse (18, 19, 22) . The lack of site specificity has been cited as part of the rationale for a reduced 2-year study protocol using only male rats and female mice (28, 29) . If tumor site cannot be reliably predicted between rodent species, extrapolation of rodent tumor sites to humans is also questionable (30) . There appears to be better transspecies tumor-site concordance across species for a relatively small select subset of IARC 1, 2A, and 2B classified pharmaceuticals (31) . This apparent concordance may be related to the genotoxic nature of a majority of the nonhormonal compounds in this group (32); even here concordance is not absolute.
Elimination of the second rodent species carcinogenicity study would significantly reduce the evidence available for regulatory decisions regarding potential carcinogenic risk and would not improve the assessment of potential human carcinogenic risk or advance the state of regulatory science. In the absence of a second species study, regulatory decisions would by necessity be based solely on the results of a conventional 2-year carcinogenicity study in one species, with important regulatory consequences. In this situation more reliance would be placed on positive tumor findings in a single study. In the absence of information to the contrary, these findings could effectively be regarded as equivalent to positive findings in two rodent species.
Use of an in Vivo Transgenic Rodent Model in Place of a Second 2-Year Rodent Carcinogenicity Study A variety of carcinogenic agents may exert their effects by a common mechanism such as the activation of protooncogenes or inactivation of tumor-suppressor genes. In vivo transgenic rodent carcinogenicity models can be used to identify mechanisms involved in tumor formation and as selective tests for carcinogens (33) . The optional substitution of a second 2-year rodent carcinogenicity study with an alternative study such as an in vivo transgenic carcinogenicity study is an approach that would contribute new insights into the mechanisms of tumorigenesis and potential human relevance. This option is part of the ICH guidance S I B: Testingfor Carcinogenicity of Pharmaceuticals (34) , which is intended to be flexible enough to accommodate a wide range of possible carcinogenicity assessment models that may be developed in the future as well as to address test models currently under consideration. Test models noted in the ICH guidance currently under consideration include initiation-promotion models, the neonatal mouse tumorigenicity assay, and in vivo transgenic rodent models. In the ICH guidance it is proposed that a single 2-year carcinogenicity study be carried out in the rodent species that best models human metabolic, pharmacokinetic, and pharmacodynamic parameters. If the rat and mouse appear equivalent in these respects, the rat likely would be considered the standard rodent model because of the greater amounts of information generally available from supporting pharmacology and toxicology studies carried out during drug development.
There is general agreement in the scientific community on the need to improve assessment of carcinogenic risk and incorporate more information on mechanisms and mode of action into the risk-assessment process. These views were expressed by the U.S. NTP Board of Scientific Counselors (35) and IARC (36) . Principles for the application of mechanisms of carcinogenesis in risk assessment were presented by IARC and include evidence of genotoxicity, i.e., structural changes at the gene level and evidence of effects on the expression of relevant genes, which would include alterations in the structure or quantity of the product of a protooncogene or tumorsuppressor gene. Evidence that similar mechanisms are acting in humans is considered important in evaluating the relevance of animal findings. For these reasons, positive findings in transgenic models could contribute more to the weight-of-evidence assessment than equivocal tumor findings in a second standard 2-year rodent study.
Transgenic models have been developed that contain regulated transgenes, unexpressed reporter genes, or knocked-out alleles of tumor-suppressor genes. Because of the relative specificity of transgenic carcinogenicity models or other factors that may influence assay sensitivity (e.g., treatment schedule, route of administration, differences in metabolism, and systemic exposure), negative findings in a single transgenic model do not rule out carcinogenic potential in the rodent. They may, however, eliminate some possible mechanisms of tumor formation. Similarly, in a standard 2-year rodent study a negative response in one strain of mice does not necessarily rule out the possibility of a significant positive finding in another mouse strain or in the rat. The significance of negative findings in any in vivo carcinogenicity bioassay is also influenced by the toxicity of the test compound relative to the minimal carcinogenic dose. For toxic compounds the maximum tolerated dose for a 2-year study could be less than the dose necessary to produce a significant tumor response and could also result in a lower systemic exposure than that attained in humans at the maximum therapeutic dose (37) . The shorter duration of exposure to test compounds for alternative carcinogenicity models (e.g., 26 weeks for transgenic models) may allow test animals to tolerate relatively higher exposures to toxic compounds than would be feasible in a 2-year carcinogenicity study.
Regulatory Application of Transgenic Mouse Models
Although not all of the mechanisms involved in the induction of cancer are known, there is a large and growing body of evidence on the critical role tumorsuppressor genes and protooncogenes play in the induction of cancer in animals and humans (38) (39) (40) . The p53 gene is an example of a major tumor-suppressor gene that is highly conserved across species and is involved in a high proportion of human cancers (41, 42 In studies with compounds tested in 2-year mouse studies and the p53-deficient mouse, there is evidence that the tumor site in p53-deficient heterozygous mice was also found in the 2-year mouse study, although not all sites found in the 2-year studies were represented in transgenic studies (15, 47 (50) . The results from the phenolphthalein p53-deficient transgenic mouse study and the known shared tumorsuppressor function of the p53 gene in rodents and humans contributed information for the weight-of-evidence assessment of the potential human relevance of the rodent tumor findings. This example also demonstrates the value of genetic analysis of tumor tissues from 2-year rodent carcinogenicity studies when there is information from transgenic models or other sources suggesting a specific carcinogenic mechanism that can be appropriately evaluated.
In a second example of the potential value of transgenic models, a low incidence of hepatoblastoma, a rare liver tumor type in mice that also occurs in children, was found in a U.S. NTP mouse carcinogenicity study of methylphenidate. This finding resulted in a notification letter to physicians. To further evaluate the carcinogenic mechanisms associated with this finding, the suitability of the mouse for human extrapolation, and the margin of safety of methylphenidate, a p53-deficient mouse study and a neonatal mouse study were carried out in addition to comparative metabolism and pharmacokinetic studies. No evidence of a carcinogenic response was observed in these studies, which contributed to the weight of evidence that suggested that the risk to humans is minimal.
Protooncogenes can be activated by processes such as point mutations, gene amplification, chromosomal translocation, and retroviral activation. Cellular oncogene products can be nuclear proteins (e.g., myc), cell membrane proteins (e.g., ras), growth factors (e.g., sis), or growth factor receptors (38) . Major ras oncogenes include the Harvey (Ha-ras) associated with human epithelial tumors and rodent tumors, the Kirsten (Ki-ras) linked to mesenchymal tumors, and the neuroblastoma (N-ras) (51) (52) (53) . Ras (40, 54) . Promising in vivo transgenic rodent models employing ras oncogenes include the TG.AC v-Ha-ras oncogene-based mouse model (15, 47) and the human c-Ha-ras transgene-based mouse model (55, 56 (15, 47) .
The selection of an alternative carcinogenicity study is expected to be scientifically justified and should include how the study can contribute additional mechanistic information that may be useful for interspecies extrapolation and the weight of evidence assessment of carcinogenic potential. Issues related to the appropriateness of the model, such as route of administration, operational characteristics of the model, level of characterization and degree of experience with the model and any relevant toxicologic issues associated with the particular pharmaceutical (e.g., genotoxicity) should be addressed. This approach would not significantly reduce-and may even enhance-the weight of evidence available for assessing potential human carcinogenic risk. Alternatively, a sponsor may conduct a second 2-year rodent carcinogenicity study.
In the United States all proposals for the use of any alternative model are reviewed by the U.S. FDA Center for Drug Evaluation Carcinogenicity Assessment Committee (CAC) prior to their initiation when requested by the sponsor. The CAC reviews the justification for the use of a particular model, the appropriateness of the model, protocol design, and dosing and offers concurrence. Concurrence on the acceptability of alternative studies can be granted only when they are formally reviewed and approved by the CAC.
Interspecies E olation
Both human and animal metabolism and pharmacokinetic information are available for human pharmaceuticals and are critical components of the risk-assessment process for both conventional rodent studies and transgenic studies. In considering the results of 2-year rat and mouse studies or transgenic rodent studies, emphasis is placed on findings from the rodent model that best approximate human metabolic and pharmacokinetic parameters. This approach was not possible until the relatively recent advent of improved chemical analytical methods for measuring the concentration of drug and major metabolites in the blood of humans and experimental animals. Comparative pharmacokinetic and metabolism information is also important for dose and test model selection for carcinogenicity studies. An evaluation of the relative systemic exposures of drugs tested at the maximum tolerated dose compared to human systemic exposure at the therapeutic dose indicated that the comparison of dose as a function of body weight generally significantly overestimates the actual relative systemic exposure of the test animal by 6-to 10-fold. For the estimation of comparative systemic exposure, dose expressed as a function of body surface area (mg/mi2) is superior to dose expressed as body weight (mg/kg) (37) . The ratio of the plasma area under the concentration-time curve for parent drug and major metabolites in rodents and humans is used to estimate the relative systemic exposure of human pharmaceuticals ("Principal Elements of the Weight-of-evidence Assessment of Carcinogenic Potential"). These approaches are applied to rodents in 2-year carcinogenicity studies and transgenic animals as was the case for phenolphthalein.
Validation of Carcinogenicity Bioassays
For regulatory application it is important to use bioassays that have been sufficiently characterized. In a discussion of the application of transgenic rodents in carcinogenicity testing, it is necessary to objectively consider the relative strengths and deficiencies of transgenic models in the context of the strengths and deficiencies of the standard 2-year rodent carcinogenicity study. The acceptability of the 2-year rodent carcinogenicity study was based on the reasonable assumption of a relationship between a biological outcome in animals (neoplasia) and potential human carcinogenic risk. Study protocols evolved over time until a relatively standard protocol developed, influenced by practical considerations of statistical power, assay sensitivity, and economic and resource considerations. The current study gained acceptance by the scientific and regulatory community after accumulation of a sufficient body of experience and demonstrated ability to identify compounds reasonably expected to be carcinogens based on human and other data. Regulatory agencies began to apply the results of rodent carcinogenicity studies on the basis of relatively limited experience with these assays. Although concern has been raised about the application of transgenic models for quantitative risk assessment, the 2-year rodent carcinogenicity study was originally intended to be a qualitative screen for potential carcinogens and may be poorly suited for quantitative risk assessment (60) .
Results of transgenic and 2-year studies will not always agree, especially for weaker (single species) carcinogens associated with species-specific mechanisms that may be less significant for human extrapolation. Lack False positive and false negative rates should be evaluated using appropriate reference compounds in a coded blinded fashion (63) . The current 2-year rodent carcinogenicity study was never validated in this manner and there is limited evidence supporting the repeatability and reproducibility of the results of the current rodent carcinogenicity study. Two-year rodent carcinogenicity studies for pharmaceuticals rarely are repeated because of their considerable cost in time and resources. When they are repeated it is generally because of failure of the original study or protocol deficiencies and therefore the results are rarely comparable because of protocol differences between studies (e.g., dose or strain differences). The reproducibility of control findings in the same study, however, can be estimated in carcinogenicity studies that incorporated a protocol with separate duplicate control groups. The U.S. NTP compiled and analyzed the results of carcinogenicity studies of 18 dyes conducted by three trade associations in the same strain and source of rats and mice and using a protocol that induded separate duplicate control groups. In 12 of 18 of the studies, statistically significant differences were found in a comparison of the tumor findings in otherwise identical control groups (64) . These findings suggest that 2-year rodent carcinogenicity studies may have poor reproducibility because of relatively high levels of variability in the spontaneous tumor incidence rate within studies. This supports the need for a second species carcinogenicity study as a confirmatory study and is in agreement with our experience with pharmaceutical carcinogenicity studies using dual identical controls. An increasing number of carcinogenicity studies for pharmaceuticals incorporate two identical but separately housed and analyzed control groups to assess variations in the spontaneous tumor incidence rate within a study.
Genetically inbred rodent strains are used in 2-year rodent carcinogenicity bioassays to minimize variability in tumor responses attributable to genetic differences. Rodent strains currently used in carcinogenicity studies were not selected on the basis of their suitability as human surrogates but for pragmatic reasons such as reasonable sensitivity to carcinogens and acceptable spontaneous tumor rate, lifespan, and animal size. The large accumulated historical record and experience with currently used rodent strains is a major reason for their continued use, although this has also retarded development of improved rodent strains. Although inbred strains are used in 2-year studies to reduce genetic diversity and variability, genetic drift is still a concern. For many rodent strains this has resulted in progressively larger, more obese animals with higher spontaneous tumor rates and reduced lifespans. This genetic drift has compromised assay sensitivity and the usefulness of some rodent strains in carcinogenicity testing and has diminished the value of the historical tumor record for these strains (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) . Many of these differences may be due to species-and strain-related (genetic) differences in metabolism and pharmacokinetics. A wide variability in spontaneous tumor incidence can also occur within a rodent strain (79, 80) . In addition it is now apparent that uncontrolled ad libitum feeding and body weight in rodent carcinogenicity studies has been an uncontrolled variable that significantly influenced the sensitivity of the bioassay to carcinogens (81) . The tumorigenic response to a potent carcinogen such as aflatoxin can be significantly altered by varying the caloric intake and body weight of rodents (82) . Assay sensitivity is equally important in the characterization of transgenic rodent models. In transgenic study protocols currendy under evaluation, a reference carcinogen at one or two dose levels is used in addition to untreated and vehicle controls to help gauge the sensitivity of the model and variations in sensitivity due to protocol or other interlaboratory study differences.
The sensitivity and variability of transgenic rodent carcinogenicity models should be evaluated in the context of the known variability in sensitivity to carcinogens and variability in spontaneous tumor responses of rodent strains used in standard 2-year carcinogenicity studies. In practice, there is flexibility in the choice of rodent test strains for 2-year carcinogenicity studies and the choice generally is left to the individual study director. Similar flexibility can be applied to transgenic rodent models if the transgenic model chosen is scientifically justified and contributes to the evaluation of human safety.
In part because of the relatively high (75%) concordance in tumor findings in rat and mouse 2-year carcinogenicity studies, the degree of experience and characterization necessary for the regulatory application of a new carcinogenicity test model to be used as a complementary study in conjunction with a single traditional 2-year rodent study could be less extensive than would be expected for a replacement of both 2-year rodent carcinogenicity studies. To encourage innovation, new emerging methods should not necessarily be expected to attain unrealistic levels of validation-levels that were never attained by current 2-year carcinogenicity studies-before they are considered for regulatory application. The extent of validation required for application of new approaches should be considered in the context of the degree of validation available for the current 2-year rodent carcinogenicity study. It interest in the development of transgenic rodent carcinogenicity models, fostered by the willingness of international regulatory agencies to consider new testing models. Because of the relatively short duration of transgenic studies, the smaller number of animals used, and their lower cost, it is anticipated that transgenic models will soon be available that are more extensively characterized than the current 2-year rodent carcinogenicity study.
Conclusions
Transgenic rodent models represent a different and complementary approach to carcinogenicity testing compared to the standard 2-year rodent study. Transgenic models have been developed that contain regulated transgenes, unexpressed reporter genes, or knocked out alleles of tumorsuppressor genes. Although transgenic models incorporating these relatively specific genetic mechanisms may not be responsive to all compounds that tested positive in the 2-year mouse or rat study, transgenic models can and have been developed that incorporate carcinogenic response elements known to be present and functioning similarly in humans. Positive findings in such transgenic models can offer valuable insights into the potential relevance and applicability of tumor findings to humans that are not readily available from standard 2-year rodent studies. Transgenic models incorporating human protooncogenes may also be the only means of identifying carcinogens that act by specific mechanisms not present in conventional rodent strains. Ironically, the relative specificity of transgenic models is viewed as a liability by some who consider the standard 2-year rodent study more widely applicable because it does not depend on any knowledge of tumorigenic mechanisms or mode of action for the assessment of human risk. It must be acknowledged, however, that the absence of such knowledge has been used to question the validity of extrapolating rodent tumor findings to humans.
In addition to their application as an alternative to a second 2-year rodent carcinogenicity study, there are other circumstances where a transgenic model may be warranted. There are occasions when a 2-year rodent study must be repeated because of inadequate survival of mice or rats, inadequate dose selection, or the need to evaluate another route of administration because of a change in the clinical indication for a drug. In such circumstances a. transgenic rodent model may be a possible alternative to repeating a 2-year carcinogenicity study. In addition the relatively short duration of the study and the reduced numbers of animals necessary for transgenic rodent studies compared to 2-year rodent studies enhance their possible usefulness as carcinogenicity screening studies for decision support early in the drug development process or in the compound selection phase.
Based on available information there is sufficient experience with some in vivo transgenic rodent carcinogenicity models to support their application as complementary second species studies in conjunction with a single 2-year rodent carcinogenicity study when appropriately justified. A properly selected transgenic mouse carcinogenicity study combined with one 2-year rat study can also adequately identify transspecies tumorigens, which are considered most relevant for the assessment of human risk. This approach will stimulate innovation and the development and application of methods that may improve assessment of potential human carcinogenic risk, which in turn will benefit public health.
